Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2010

View Archived Issues

Novexel discloses novel antibacterial agents

Novel SAPK1/JNK1 inhibitors identified by U.S. researchers

Array BioPharma discloses novel receptor tyrosine kinase inhibitors

Janus kinase inhibitors for cancer therapy claimed by Rigel Pharmaceuticals

U.S. scientists identify novel viral and fungal inhibitors

IMPACT-DCM results encourage larger trials of cardiac repair cells in dilated cardiomyopathy

Polo-like kinase 1 inhibitors from Cyclacel active in xenograft cancer models

LigoCyte updates norovirus vaccine clinical development progress

Cleveland Biolabs describes novel curaxin radiosensitizers for cancer

Phase III study of Roche's taspoglutide in type 2 diabetes meets primary endpoint

Novavax reports results for seasonal influenza VLP vaccine candidate

Pepscan and Immunovo sign agreement for Pepscan's therapeutic vaccine portfolio

Mydicar meets primary endpoint in phase II advanced heart failure trial

BioTime to acquire ES Cell International for development of stem cell-based therapeutics

TxCell reports preliminary results from phase I/IIa trial of OvaSave in Crohn's disease

BioMarin plans phase III trial of GALNS in MPS IVA following phase I/II results

Phase III Trinity study results reported for olmesartan/amlodipine/HCTZ in hypertension

Artisan completes enrollment in phase IIb ART-123 study in sepsis patients

Dynavax receives clearance to start two phase III Heplisav trials

Pieris reports preclinical data for its c-Met Anticalin drug

Celtic Therapeutics acquires rights to Kiacta from BELLUS Health

EnzymeRx reports phase I results for pegsitacase

Provectus reports on end-of-phase II meeting with FDA for PV-10

BARDA exercises options on Cleveland BioLabs contract to develop CBLB-502

FDA approves Vimovo delayed-release tablets for arthritis patients

Palmitoylethanolamide enhances efficacy of topical ocular antihypertensive treatments

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...